Literature DB >> 11953043

Development of a closed-system process for clinical-scale generation of DCs: evaluation of two monocyte-enrichment methods and two culture containers.

E C C Wong1, S M Lee, K Hines, J Lee, C S Carter, W Kopp, J Bender, E J Read.   

Abstract

BACKGROUND: Clinical immunotherapy trials using DCs depend on large-scale methods for DC generation that fulfil current good manufacturing practice requirements. Our goal was to develop data on two variables, monocyte-enrichment method and culture container, which could be used to design a closed-system process for ex vivo generation of immature DCs.
METHODS: Mononuclear cells were collected by leukapheresis and enriched for monocytes by either counterflow centrifugal elutriation, or immunomagnetic selection using Isolex, an automated closed-system device. Monocytes were cultured for 7 days in serum-free medium with GM-CSF and IL-4, using either plastic flasks or gas-permeable Stericell bags. Monocytes and cultured DCs were evaluated for yield, flow cytometric phenotype, and in vitro function in MLR, and autologous recall responses to tetanus toxoid and influenza virus.
RESULTS: Enriched monocyte products from elutriation and immunomagnetic selection were equivalent in yield and purity, and were capable of generating immature DCs in either flasks or bags. DCs from all four culture conditions were equivalent in yield, phenotype, and in vitro function. Mean DC yield was 67-80% per seeding monocyte, and 11-13% per starting mononuclear cell (MNC). A leukapheresis product containing 5 x 10(9) MNCs processed by this method could therefore yield approximately 5 x 10(8) immature DCs. DISCUSSION: In this manufacturing process, the Isolex system was equivalent to elutriation, and Stericell bags were equivalent to flasks. Together, the Isolex system and Stericell bags can be incorporated into a closed-system process to generate immature DCs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11953043     DOI: 10.1080/146532402317251545

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  3 in total

Review 1.  Human dendritic cells and transplant outcome.

Authors:  Mario G Solari; Angus W Thomson
Journal:  Transplantation       Date:  2008-06-15       Impact factor: 4.939

2.  Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate.

Authors:  Cheryl L-L Chiang; Dawn A Maier; Lana E Kandalaft; Andrea L Brennan; Evripidis Lanitis; Qunrui Ye; Bruce L Levine; Brian J Czerniecki; Daniel J Powell; George Coukos
Journal:  J Transl Med       Date:  2011-11-14       Impact factor: 5.531

3.  Closing the system: production of viral antigen-presenting dendritic cells eliciting specific CD8+ T cell activation in fluorinated ethylene propylene cell culture bags.

Authors:  Jean-Philippe Bastien; Natalie Fekete; Ariane V Beland; Marie-Paule Lachambre; Veronique Laforte; David Juncker; Vibhuti Dave; Denis-Claude Roy; Corinne A Hoesli
Journal:  J Transl Med       Date:  2020-10-09       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.